Yes, ketamine can cause depression in certain circumstances, despite being widely known as a fast-acting antidepressant. The answer depends heavily on context: who is using it, how much, how often, and for how long. In healthy people with no depression, a single clinical dose can temporarily increase depressive symptoms for up to 24 hours. In chronic recreational users, long-term use is linked to lasting mood disorders and measurable brain changes. And stopping ketamine after regular use can trigger depression as a withdrawal symptom.
How Ketamine Affects Mood in Healthy People
One of the more surprising findings in ketamine research is that the drug appears to have opposite mood effects depending on whether someone is already depressed. A study published in Molecular Psychiatry gave a standard clinical dose to both people with major depression and healthy volunteers. The depressed participants improved, as expected. But 71% of the healthy participants (17 out of 24) experienced a meaningful increase in depressive symptoms after receiving ketamine, compared to just 4% of those who received a placebo.
These symptoms showed up within 40 minutes of the infusion and persisted for up to one day, primarily in the form of increased anxiety and anhedonia (the inability to feel pleasure). By the second day, nearly all healthy participants had returned to baseline. The effect was temporary, but it was real and statistically significant. This suggests that ketamine’s interaction with the brain’s glutamate system, which drives its antidepressant benefits in depressed patients, can push mood in the wrong direction when that system is already functioning normally.
The Inverted U-Shaped Dose Curve
Ketamine’s mood effects follow what researchers describe as an “inverted U-shaped” dose-response curve. Moderate subanesthetic doses, particularly around 0.5 mg/kg delivered intravenously, produce the most consistent antidepressant effects. Doses that are too low (such as 0.2 mg/kg) tend to be less effective for serious depression, while higher doses don’t necessarily work better and come with a greater risk of side effects including dissociation, dysphoria, and perceptual disturbances. Faster infusion rates also increase the likelihood of these psychological side effects.
This means there’s a relatively narrow therapeutic window. Outside of it, particularly at higher doses or with rapid delivery, the drug is more likely to cause distressing mood changes rather than relief.
Long-Term Recreational Use and Brain Changes
The most concerning link between ketamine and depression involves chronic recreational use. A systematic review examining brain imaging studies across 440 long-term ketamine users (who had been using for 2 to nearly 10 years, often consuming more than 1 gram daily) found consistent structural and functional brain changes. These users showed lower gray matter volume in several regions of the frontal cortex, reduced white matter integrity, and weaker connections between brain areas involved in mood regulation and decision-making.
The specific regions affected are telling. Chronic users had smaller volumes in the prefrontal cortex, the orbitofrontal cortex, the hippocampus, and the nucleus accumbens, all areas closely tied to emotional processing, motivation, and reward. The longer someone had used ketamine, the more extensive the cortical atrophy. And the severity of these brain changes correlated directly with worse cognitive performance and higher scores on depression rating scales. In female chronic users specifically, altered connectivity between mood-regulating brain regions was strongly associated with depressive symptoms.
To put the doses in perspective, the recreational users in these studies were consuming roughly 25 to 70 times the standard clinical dose. This is a fundamentally different exposure than what occurs in a supervised treatment setting, but it demonstrates that high-dose, prolonged ketamine use can cause the kind of brain changes associated with depression and cognitive decline.
Withdrawal and Post-Cessation Depression
When someone who has been using ketamine regularly stops, depression is one of the most common withdrawal symptoms. The timeline follows a predictable pattern. Psychological symptoms, including cravings, anxiety, and irritability, begin within the first 24 to 72 hours. Between days 3 and 7, these symptoms peak, with depression, anxiety, and insomnia often at their worst. Over the following weeks, mood swings and fatigue gradually ease.
For people with a history of heavy or prolonged use, the recovery can stretch much longer. Mild depression, intermittent cravings, and sleep problems can persist for several months after the last dose. This protracted withdrawal phase is one reason relapse rates are high: the lingering low mood creates a strong pull to use again.
Physical Side Effects That Fuel Depression
Chronic ketamine use also causes physical problems that can independently worsen mood. One of the most well-documented is ketamine-associated bladder damage, which causes painful and frequent urination. A study investigating risk factors for these urinary symptoms found that ketamine users with depression had symptom severity scores 1.63 times higher than users without depression. Depression and longer duration of ketamine exposure were the two factors most strongly associated with developing these bladder problems, creating a cycle where physical pain and emotional distress reinforce each other.
What About Prescription Ketamine Treatment?
For people considering or currently receiving ketamine therapy for depression, the picture is more reassuring. Esketamine (the nasal spray form approved by the FDA under the brand name Spravato) carries a boxed warning about suicidal thoughts and behaviors, but this is the same class warning required for all antidepressants, particularly regarding young adults. In clinical trials, treatment-emergent suicidal ideation occurred in about 6.6 to 6.7% of participants receiving esketamine, compared to 9.6% of those on placebo, meaning suicidal thoughts were actually more common in the placebo group.
Common side effects during clinical treatment include transient dissociation, dizziness, nausea, mild blood pressure increases, and brief periods of dysphoria or anxiety. These typically resolve within hours of administration. The transient mood dip seen in healthy volunteers has not been a prominent concern in depressed patients receiving therapeutic doses, likely because the drug is correcting an existing imbalance rather than disrupting a healthy one.
The critical distinction across all of these scenarios is dose, frequency, and baseline brain chemistry. At clinical doses in supervised settings, ketamine is one of the most effective tools available for treatment-resistant depression. At recreational doses over months or years, it can cause the very condition it was designed to treat.